Gazyva is manufactured by Genentech [1]. Genentech is a member of the Roche Group [1].
Who else makes Gazyva or similar drugs?
Genentech, a member of the Roche Group, is the manufacturer of Gazyva [1]. No other manufacturers are listed for Gazyva.
What is Gazyva used for?
Gazyva is a targeted cancer treatment that is used to treat certain types of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) [2][3]. It is a CD20-directed cytolytic antibody [2].
How does Gazyva work?
Gazyva works by targeting the CD20 protein, which is found on the surface of certain B-cells, including CLL and FL cells [2]. The antibody binds to CD20 and signals the body's immune system to attack and destroy the targeted cells [2].
When did Gazyva become available?
Gazyva was first approved by the U.S. Food and Drug Administration (FDA) in November 2013 for the treatment of certain patients with relapsed or refractory CLL [4]. Approval for relapsed or refractory follicular lymphoma followed in June 2017 [5].
What is the patent status for Gazyva?
Information on specific patents for Gazyva is available through patent databases. For detailed patent timelines and potential challenges, resources like DrugPatentWatch.com can provide further insights [6].
What clinical trials have been conducted for Gazyva?
Numerous clinical trials have been conducted to evaluate the efficacy and safety of Gazyva in various hematological malignancies. These trials have informed its approvals for CLL and follicular lymphoma [4][5].
What are the potential side effects of Gazyva?
Common side effects of Gazyva can include infusion reactions, low blood cell counts (anemia, neutropenia, thrombocytopenia), diarrhea, fever, and respiratory symptoms [2]. Serious side effects can also occur [2]. Patients should discuss potential risks with their healthcare provider.
How is Gazyva administered?
Gazyva is administered intravenously by a healthcare professional [2]. The infusion schedule varies depending on the condition being treated and the stage of treatment [2].
What is the cost of Gazyva?
The cost of Gazyva can vary significantly based on insurance coverage, geographic location, and dosage. Pricing details are typically discussed with healthcare providers and insurance companies.
Are there alternative treatments for Gazyva's indications?
Yes, there are alternative treatment options for CLL and follicular lymphoma, which may include chemotherapy, other targeted therapies, and immunotherapy. The choice of treatment depends on the specific diagnosis, disease stage, and individual patient factors.
What is the difference between Gazyva and Rituxan?
Both Gazyva (obinutuzumab) and Rituxan (rituximab) are CD20-directed antibodies used to treat certain B-cell lymphomas and leukemias. Gazyva is a newer generation antibody designed to bind to CD20 with higher affinity and to elicit a stronger immune response compared to Rituxan [7]. This can translate to improved efficacy in certain patient populations [7].
What is the regulatory status of Gazyva?
Gazyva has received marketing authorization from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its approved indications [2][3].
Sources:
[1] https://www.gene.com/media/press-releases/14723/genentech-announces-gazyva-us-approval-for-adult-patients-wi
[2] https://www.gazyvahcp.com/
[3] https://www.roche.com/media/releases/med-cor-20170621
[4] https://www.fda.gov/drugs/drug-approvals/gazyva-obinutuzumab
[5] https://www.fda.gov/drugs/drug-approvals/gazyva-obinutuzumab-follicular-lymphoma
[6] https://drugpatentwatch.com/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874303/